Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children.
Allogeneic (allo) hematopoietic cell transplantation (HCT) has evolved into a potent curative treatment option for a variety of malignant and nonmalignant diseases. The occurrence of complications and mortality after allo-HCT is, however, still high and is strongly associated with immune reconstitution (IR). Therefore, detailed information on IR through immunomonitoring is crucial to improve survival chances after HCT. To date, information about the reconstituting immune system after allo-HCT in pediatric patients is mostly derived from routine standard-of-care measurements. More profound knowledge on IR may provide tools to better predict and modulate adverse reactions and, subsequently, improve survival chances. Here, we provide an overview of IR (eg, immune cell subsets and circulating chemokines/cytokines) after allo-HCT in children, taking into account different cell sources and serotherapy, and discuss strategies to enhance immunomonitoring. We conclude that available IR data after allo-HCT contain limited information on immune cell families (mostly only generic T, B, and NK cells), which would improve with more detailed information on reconstituting cell subsets or effector cell functionality at earlier time points (<1 month). In addition, secretome data (eg, multiplex cytokine/chemokine profiles) could add to the understanding of IR mechanisms and cell functionality and may even provide (early) biomarkers for individual disease outcome, such as viral reactivity, graft-versus-host disease, or graft-versus-leukemia. The present data and suggestions for more detailed, standardized, and harmonized immunomonitoring in future (pediatric) allo-HCT studies will pave the path to "precision transplantation:" an individualized HCT approach (including conditioning), based on detailed information on IR and biomarkers, aiming to reduce transplantation related mortality and relapse, and subsequently improve survival chances.
Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Coco
C
de Koning
Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Maud
M
Plantinga
Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Paul
P
Besseling
Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands; Pediatric Blood and Marrow Transplantation Program, University Medical Centre Utrecht, Utrecht, The Netherlands.
Jaap Jan
JJ
Boelens
Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands. Electronic address: snierken@umcutrecht.nl.
Stefan
S
Nierkens
D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*
D015415:Biomarkers
Allogeneic hematopoietic cell transplantation; Biomarkers; Immune reconstitution; Pediatric patients; Secretome; Serotherapy